The JHU technology leverages an epigenetic biomarker panel and a sponge-on-a-string collection device, as well as a PCR-based method, to detect Barrett's esophagus.
The Israeli firm recently announced the results of a multicenter study of its Bladder EpiCheck test in addition to netting €2.5 million in EU funding to develop a lung cancer assay.
The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
The company has contracted with a urologist, who will review customers' requests for tests, and prescribe the firm's epigenetics-based male fertility analysis.
The company's test measures epigenetic alteration of two genes using Qiagen PCR methods, in order to detect signs of recurrence in colorectal cancer patients post-surgery.
